Analysts Set Alector, Inc. (NASDAQ:ALEC) Price Target at $14.00

Alector, Inc. (NASDAQ:ALEC) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.

A number of brokerages have commented on ALEC. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research report on Thursday, June 20th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Alector in a report on Thursday, June 20th.

Insider Buying and Selling

In other Alector news, CEO Arnon Rosenthal sold 25,135 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $120,648.00. Following the sale, the chief executive officer now owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Gary Romano sold 8,040 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $38,592.00. Following the completion of the transaction, the insider now owns 188,273 shares in the company, valued at $903,710.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Arnon Rosenthal sold 25,135 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The disclosure for this sale can be found here. Insiders have sold a total of 40,095 shares of company stock valued at $192,456 over the last three months. 9.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALEC. Gladius Capital Management LP bought a new stake in shares of Alector during the 2nd quarter valued at about $29,000. Allspring Global Investments Holdings LLC bought a new stake in Alector during the 1st quarter valued at approximately $40,000. Lazard Asset Management LLC purchased a new position in shares of Alector during the 1st quarter worth approximately $59,000. China Universal Asset Management Co. Ltd. raised its position in shares of Alector by 352.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,733 shares of the company’s stock worth $78,000 after acquiring an additional 7,584 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Alector in the 4th quarter valued at approximately $81,000. 85.83% of the stock is currently owned by institutional investors.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $6.49 on Monday. The company’s fifty day moving average price is $5.02 and its 200-day moving average price is $5.71. The firm has a market capitalization of $625.57 million, a price-to-earnings ratio of -4.70 and a beta of 0.73. Alector has a one year low of $3.66 and a one year high of $9.06.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. The business had revenue of $15.89 million for the quarter, compared to analysts’ expectations of $14.63 million. As a group, equities research analysts expect that Alector will post -1.93 EPS for the current year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.